Zentalis Pharmaceuticals ZNTL Institutional Ownership

Updated Oct 11, 2026

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) had 116 institutional holders reporting a position on Form 13F for the quarter ended June 30, 2026.

• These investors held 66.12% of Zentalis Pharmaceuticals' outstanding shares at the end of Q2 2026, up from 61.22% in Q1 2026.
• Total shares held in ZNTL rose 8.78% from Q1 2026; the number of holders rose 0.87% from Q2 2025.
• Of the 116 holders of ZNTL in Q2 2026, 64 added to their positions, 32 reduced their stakes and 20 left their positions unchanged.
• Institutional investors held 47.38Mn shares of Zentalis Pharmaceuticals in total at the end of Q2 2026, up 3.82Mn from the prior quarter and down 6.71Mn from a year earlier.
• 5AM Venture Management, LLC was the top holder of Zentalis Pharmaceuticals as of June 30, 2026, with 3.95Mn shares, or 5.51% of shares outstanding.
• Among holders that already owned Zentalis Pharmaceuticals, the biggest buyers in Q2 2026 were BlackRock, Inc. (+2.48Mn shares), Geode Capital Management, LLC (+663.08K shares), State Street Corp (+637.73K shares), Citadel Advisors LLC (+566.32K shares) and Vanguard Capital Management LLC (+524.96K shares).
• The largest position reductions in ZNTL for Q2 2026 were by D. E. Shaw & Co., Inc. (-937.53K shares), Millennium Management LLC (-625.54K shares), Jane Street Group, LLC (-475.94K shares), BNP Paribas Financial Markets (-458.96K shares) and Barclays PLC (-432.36K shares).
• Per Business Quant data, the 10 largest holders of Zentalis Pharmaceuticals at the end of Q2 2026 were 5AM Venture Management, LLC (3.95Mn shares), BlackRock, Inc. (3.75Mn shares), Squadron Capital Management LLC (3.7Mn shares), Two Sigma Investments, LP (3.02Mn shares), Vanguard Capital Management LLC (2.84Mn shares), Acadian Asset Management LLC (2.68Mn shares), Citadel Advisors LLC (2.3Mn shares), Renaissance Technologies LLC (1.61Mn shares), Opaleye Management Inc. (1.41Mn shares) and OrbiMed Advisors LLC (1.39Mn shares).